CN114835678A - Salts of indole derivatives and uses thereof - Google Patents

Abstract

The invention belongs to the technical field of medicines, and relates to salts of indole derivatives and application thereof. The invention also relates to a crystal form of the salt, a pharmaceutical composition containing the salt and/or the crystal form, and the use of the salt, the crystal form and/or the pharmaceutical composition in preparation of a medicament for preventing, treating or reducing PGD at CRTH2 receptor ₂ The use of the mediated diseases, in particular asthma and allergic rhinitis.

Description

Salts of indole derivatives and uses thereof

Technical Field

The invention belongs to the technical field of medicines, relates to salts of indole derivatives and application thereof, and particularly relates to salts of 2- (5-fluoro-3- (1- ((4-fluorophenyl) sulfonyl) piperidin-4-yl) -2-methyl-1H-indol-1-yl) acetic acid, crystal forms of the salts and pharmaceutical compositions containing the salts, and further relates to application of the salts, the crystal forms of the salts or the pharmaceutical compositions.

Background

CRTH2 is a G protein-coupled chemoattractant receptor, and is expressed on Th2 cells and eosinophils. Th2 polarization has been observed in allergic diseases such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis. Th2 cells regulate allergic diseases by producing Th2 cytokines such as IL-4, IL-5 and IL-13. In allergic diseases, these Th2 cytokines induce migration, activation, triggering and prolonged survival of effector cells, such as eosinophils and basophils, directly or indirectly.

PGD ₂ (prostaglandin D2), a ligand of CRTH2, is composed of mast cells in allergic diseasesCells and other important effector cells. In human cells, PGD ₂ Migration and activation of Th2 cells, eosinophils and basophils were induced by CRTH 2. Thus, antagonism of PGD at the CRTH2 receptor ₂ Is an attractive approach for the treatment of Th 2-dependent allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. CRTH2 receptor antagonists have also been reported to be useful for the treatment of other eosinophil-associated diseases, such as allergic granulomatous vasculitis and sinusitis.

International application WO2016037591a1 discloses the compound 2- (5-fluoro-3- (1- ((4-fluorophenyl) sulfonyl) piperidin-4-yl) -2-methyl-1H-indol-1-yl) acetic acid (compound represented by formula (I)) having CRTH2 receptor antagonistic activity and a crystalline form thereof. However, the prior art does not study on the salt of the compound or the crystal form of the salt.

Different salts and solid forms of a pharmaceutically active ingredient may have different properties. Different salts and solid forms may have significant differences in appearance, solubility, melting point, dissolution rate, bioavailability, etc., and may also have different effects on the stability, bioavailability, therapeutic effect, etc. of the drug. Therefore, in drug development, the problem of salt form and/or solid form of the drug should be fully considered.

The inventor researches the compound to find that the crystal form I has better properties compared with other crystal forms of the compound, but the crystal form I has poor water solubility and poor drugability and is not beneficial to drug development. Through a large number of experimental researches, the inventor finds that after the compound shown in the formula (I) forms a salt, the physicochemical properties of different salts are greatly changed, and the properties of some salts are not better than those of the compound in a free state; the physical properties and various properties of the sodium salt and the magnesium salt of the compound shown in the formula (I) prepared by the method can be obviously improved, and the preparation development is facilitated.

Disclosure of Invention

The invention provides a salt of a compound shown as a formula (I), and researches on a preparation method of the salt, a solid form of the salt, physical and chemical properties and pharmacological properties of the salt are carried out, so that the physical and chemical properties of the salt formed by the compound and different inorganic bases are greatly different; wherein, the calcium salt formed by the compound shown in the formula (I) has poorer pharmacological property than the compound shown in the formula (I); various physical and chemical properties of the sodium salt and/or the magnesium salt are better than those of the compound shown in the formula (I) and other salts, for example, the crystal form I of the sodium salt obtained after the compound shown in the formula (I) and sodium isooctanoate are salified and/or the crystal form I of the magnesium salt obtained after the compound shown in the formula (I) and magnesium chloride are salified, and the pharmacokinetic properties such as half-life period of the crystal form I of the compound and the crystal form II of the sodium salt and the crystal form I of the calcium salt are better than those of the crystal form I of the compound and the crystal form II of the sodium salt and the crystal form I of the calcium salt. Therefore, the sodium salt crystal form I and the magnesium salt crystal form I have better properties and better pharmacokinetic properties, so that the sodium salt crystal form I and the magnesium salt crystal form I have better drugability.

In particular, the invention relates to a salt of a compound shown as a formula (I), a crystal form of the salt or a pharmaceutical composition containing the salt or the crystal form of the salt, and application of the salt or the pharmaceutical composition in preparation of a medicine for preventing, treating or reducing PGD on CRTH2 receptor of a patient ₂ The use of the mediated diseases, in particular asthma and allergic rhinitis. The salt of the invention is a sodium salt and/or a magnesium salt. Further, the salt provided by the invention is sodium salt crystal form I and/or magnesium salt crystal form I. The crystalline forms of the present invention may also be in the form of solvates, for example hydrates.

In one aspect, the invention provides a salt of a compound of formula (I),

in some embodiments, the salts described herein are inorganic base salts.

In other embodiments, the inorganic base salts described herein include, but are not limited to, sodium, calcium, or magnesium salts, and the like.

In some embodiments, the salt of the compound of formula (I) of the present invention is a sodium salt.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.97 ° ± 0.2 °,16.28 ° ± 0.2 °,17.83 ° ± 0.2 °,18.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.61 ° ± 0.2 °,22.60 ° ± 0.2 °.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.97 ° ± 0.2 °,11.87 ° ± 0.2 °,12.82 ° ± 0.2 °,16.28 ° ± 0.2 °,17.83 ° ± 0.2 °,18.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.61 ° ± 0.2 °,21.26 ° ± 0.2 °,22.60 ° ± 0.2 °.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.97 ° ± 0.2 °,8.73 ° ± 0.2 °,9.15 ° ± 0.2 °,9.70 ° ± 0.2 °,10.10 ° ± 0.2 °,10.40 ° ± 0.2 °,10.88 ° ± 0.2 °,11.87 ° ± 0.2 °,12.82 ° ± 0.2 °,14.89 ° ± 0.2 °,15.35 ° ± 0.2 °,15.74 ° ± 0.2 °,16.28 ° ± 0.2 °,16.78 ° ± 0.2 °,17.05 ° ± 0.2 °,17.30 ° ± 0.2 °,17.83 ° ± 0.2 °,18.36 ° ± 0.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.16 ° ± 0.61 °, 20.21.26 ° ± 0.2.2 ± 0.26 ° ± 0.2 °,18 ° ± 0.2 °,19 ° ± 0.2.2 ° ± 0.2 °,20.2 °,20.61 ° ± 0.26 ° ± 0.2 °, 2.2 °,2 ° ± 0.2.2 °,2 °, 2.2 °,2 ° ± 0.2 °, 2.2.2.2 ° ± 0.2 °,2 ° ± 0.2.2.2 °, 2.2 °,2 °, 2.2.2 ° ± 0.2 °,2 °, 2.2.2 °,2 °, 2.2 °,2 ° 0.2.2 ° 0.2 °,2 ° 0.2 °, 2.2 ° 0.2 °, 0.2 ° 0.2.2.2 °, 0.2 ° 0.2.2 °, 0.2 °,2 °, 0.2 °, 2.2 ° 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °,0, 33.49 ° ± 0.2 °,35.06 ° ± 0.2 °,35.52 ° ± 0.2 °,36.67 ° ± 0.2 °,37.84 ° ± 0.2 °,38.59 ° ± 0.2 °,38.98 ° ± 0.2 °,40.37 ° ± 0.2 °.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern substantially as shown in figure 1.

In some embodiments, the salt of the invention is a sodium salt, characterized in that the sodium salt is sodium salt form I having a differential scanning calorimetry trace comprising an endothermic peak at 210.79 ℃ ± 3 ℃.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I having a differential scanning calorimetry pattern substantially as shown in figure 2.

In some embodiments, the salt of the present invention is a sodium salt, wherein the sodium salt is sodium salt form I, and wherein the weight loss of the sodium salt form I is about 0.5670% when heated to about 154.59 ℃.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form I, wherein the sodium salt form I has a thermogravimetric analysis profile substantially as shown in figure 3.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II, wherein the sodium salt form II has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 10.07 ° ± 0.2 °,18.17 ° ± 0.2 °,19.09 ° ± 0.2 °,20.16 ° ± 0.2 °,27.53 ° ± 0.2 °.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II, wherein the sodium salt form II has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.06 ° ± 0.2 °,9.09 ° ± 0.2 °,10.07 ° ± 0.2 °,13.63 ° ± 0.2 °,18.17 ° ± 0.2 °,18.49 ° ± 0.2 °,18.74 ° ± 0.2 °,19.09 ° ± 0.2 °,20.16 ° ± 0.2 °,27.53 ° ± 0.2 °.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II, wherein the sodium salt form II has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.06 ° ± 0.2 °,8.28 ° ± 0.2 °,8.81 ° ± 0.2 °,9.09 ° ± 0.2 °,10.07 ° ± 0.2 °,11.42 ° ± 0.2 °,12.45 ° ± 0.2 °,13.31 ° ± 0.2 °,13.63 ° ± 0.2 °,14.43 ° ± 0.2 °,15.12 ° ± 0.2 °,16.12 ° ± 0.2 °,16.45 ° ± 0.2 °,18.17 ° ± 0.2 °,18.49 ° ± 0.2 °,18.74 ° ± 0.2 °,19.09 ° ± 0.2 °,20.16 ° ± 0.2 °,22.01 ° ± 0.2 °,22.75 ° ± 0.2 °,23.09 ° ± 0.23.97 ° ± 0.25 ° ± 0.2.2 °,20 ° ± 0.79 ° ± 0.2 °, 22.2 °, 22.0.0 ° ± 0.3 ° ± 0.26 ° ± 0.2 °, 2.26 ° ± 2 °, 22.26 ° ± 2.2 °, 22.2 °,23.09 ° ± 0.38 ° ± 0.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.3 ° ± 0.2.2 °, 2.2.3 ° ± 0.2 °, 2.2.2 °,2 °,3 ° ± 0.2 °, 2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.9 ° ± 0.2.2 °,3 ° ± 0.2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2.2.2.2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2.2.2 °,3 ° ± 0.2 °,3 ° ± 0.2.2 °,3 ° ± 0.2.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II having an X-ray powder diffraction pattern substantially as shown in figure 4.

In some embodiments, the salt of the invention is a sodium salt, characterized in that the sodium salt is sodium salt form II having a differential scanning calorimetry trace comprising endothermic peaks at 104.40 ℃ ± 3 ℃ and 184.48 ℃ ± 3 ℃.

In some embodiments, the salt of the invention is a sodium salt, characterized in that the sodium salt is sodium salt form II having a differential scanning calorimetry pattern substantially as shown in figure 5.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II, wherein the sodium salt form II loses about 5.606% weight when heated to about 79.98 ℃, loses about 1.388% weight again when heated to about 139.30 ℃, and loses about 0.7184% weight for the third time when heated to about 182.72 ℃.

In some embodiments, the salt of the invention is a sodium salt, wherein the sodium salt is sodium salt form II having a thermogravimetric analysis profile substantially as shown in figure 6.

In some embodiments, the salt of the compound of formula (I) of the present invention is a magnesium salt.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I, wherein the magnesium salt form I has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 16.33 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,28.93 ° ± 0.2 °.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I, wherein the magnesium salt form I has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 13.26 ° ± 0.2 °,16.33 ° ± 0.2 °,16.78 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,22.06 ° ± 0.2 °,28.93 ° ± 0.2 °.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I, wherein the magnesium salt form I has an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.15 ° ± 0.2 °,8.40 ° ± 0.2 °,9.25 ° ± 0.2 °,10.31 ° ± 0.2 °,12.19 ° ± 0.2 °,13.26 ° ± 0.2 °,14.28 ° ± 0.2 °,14.62 ° ± 0.2 °,15.50 ° ± 0.2 °,16.33 ° ± 0.2 °,16.78 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,20.24 ° ± 0.2 °,20.61 ° ± 0.2 °,21.10 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,22.06 ° ± 0.2 °,22.99 ° ± 0.2 °,23.59 ° ± 0.2 °,23.95 ° ± 0.2.2 ° ± 0.2 °, 2.2 ° ± 0.2 °, 2.9 ° ± 0.9 ° ± 0.2 °, 2.2 °,2 °, 2.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.2 °, 2.9 ° ± 0.9 ° ± 0.2 °, 2.2.2.2 °, 2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2.2 °, 2.2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °,2 °, 2.2 °,2 °, 2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.2.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °, 2.2.2.2.2.9 ° ± 0.2.2 °, 2.2.2 °,2 °, 2.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2 °,2 °, 2.2 °, 2.2.2 °,2 °, 2.2 °,2 °, 2.2.9 ° ± 0, 42.10 ° ± 0.2 °,44.08 ° ± 0.2 °,49.00 ° ± 0.2 °.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I having an X-ray powder diffraction pattern substantially as shown in figure 7.

In some embodiments, the salt of the invention is a magnesium salt, characterized in that the magnesium salt is magnesium salt form I having a differential scanning calorimetry trace comprising an endothermic peak at 160.86 ℃ ± 3 ℃.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I having a differential scanning calorimetry trace substantially as shown in figure 8.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I, wherein the weight loss of the magnesium salt form I is about 4.377% when the magnesium salt form I is heated to about 94.45 ℃, and the weight loss of the magnesium salt form I is about 5.385% again when the magnesium salt form I is continuously heated to about 130.13 ℃.

In some embodiments, the salt of the invention is a magnesium salt, wherein the magnesium salt is magnesium salt form I having a thermogravimetric analysis profile substantially as shown in figure 9.

In some embodiments, the salt of the compound of formula (I) of the present invention is a calcium salt.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 9.69 ° ± 0.2 °,15.05 ° ± 0.2 °,18.48 ° ± 0.2 °,19.47 ° ± 0.2 °,19.91 ° ± 0.2 °.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 9.69 ° ± 0.2 °,10.86 ° ± 0.2 °,14.65 ° ± 0.2 °,15.05 ° ± 0.2 °,18.48 ° ± 0.2 °,18.88 ° ± 0.2 °,19.47 ° ± 0.2 °,19.91 ° ± 0.2 °,21.81 ° ± 0.2 °,23.48 ° ± 0.2 °.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.46 ° ± 0.2 °,9.69 ° ± 0.2 °,10.86 ° ± 0.2 °,12.40 ° ± 0.2 °,14.65 ° ± 0.2 °,15.05 ° ± 0.2 °,15.68 ° ± 0.2 °,16.37 ° ± 0.2 °,16.90 ° ± 0.2 °,17.61 ° ± 0.2 °,18.00 ° ± 0.2 °,18.48 ° ± 0.2 °,18.88 ° ± 0.2 °,19.47 ° ± 0.2 °,19.91 ° ± 0.2 °,20.41 ° ± 0.2 °,21.35 ° ± 0.2 °,21.81 ° ± 0.2 ° ± 0.59 ° ± 0.2 °,23.48 ° ± 0.2 °,24.10 ° ± 0.2 °,24.90 ° ± 0.2.92 ° ± 0.27.2 ° ± 0.2 °, 21.27 ° ± 0.2 °,23.48 ° ± 0.2 ° ± 0.2.2 °,24.9 ° ± 2 ° ± 2.2 °, 2.2.2 ° ± 2 °, 2.33 ° ± 2.2 °,2 °, 2.2 °,24.9 ° ± 0.33 ° ± 2.33 ° ± 2 °, 2.2 °, 2.2.2.2 ° ± 0.2 °,2 °, 2.2.2 °, 2.2 ° ± 0.2.9 ° ± 0.33 ° ± 0.2 °,2 °, 2.2.2 °,2 °, 2.2 °, 2.2.9 ° ± 0.2.2.2.2 ° ± 0.2 °,2 °, 2.2.2 ° ± 0.9 ° ± 0.2.33 ° ± 0.33 ° ± 0.2.2 °, 2.2.2 °, 2.2 ° ± 0.2 ° ± 0.2.2.2 °,2 °, 2.2.2.2.2.9 ° ± 0.2 °,2 °, 2.2.2 °,2 ° ± 0.2 °,2 ° ± 0.9 ° ± 0.2 ° ± 0.9 ° ± 0.33 ° ± 0.2.33 ° ± 0.33 ° ± 0.2 °,2 °, 2.33 ° ± 0.2 °,2 °, 2.33 ° ± 0.2.2 °, 2.2.2 °,2 °, 2.2 °, 2.33 ° ± 0.2.2.2 °,2 °, 2.2.2.2.2 °,2 °, 2.2.2 °, 2.2.2.2 °,2 ° ± 0.2.2.2.2.2.2 °,2 ° ± 0.2 ° ± 0.2.2.33 ° ± 0.2.2 ° ± 0.33 ° ± 0.2 °,2 ° ± 0.2 °, 2.2 °,2 °, 2.2 °,2.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having an X-ray powder diffraction pattern substantially as shown in figure 10.

In some embodiments, the salt of the invention is a calcium salt, characterized in that the calcium salt is calcium salt form I having a differential scanning calorimetry trace comprising endothermic peaks at 111.94 ℃ ± 3 ℃ and 204.22 ℃ ± 3 ℃.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having a differential scanning calorimetry pattern substantially as shown in figure 11.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is form I of the calcium salt, wherein the weight loss of form I of the calcium salt is about 3.001% when the salt is heated to about 88.54 ℃, and the weight loss of form I of the calcium salt is about 3.815% when the salt is further heated to about 168.04 ℃.

In some embodiments, the salt of the invention is a calcium salt, wherein the calcium salt is calcium salt form I having a thermogravimetric analysis profile substantially as shown in figure 12.

In another aspect, the invention relates to a pharmaceutical composition comprising any one of the salts described herein, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, or combination thereof.

In one aspect, the invention relates to the use of said salt or said pharmaceutical composition for the preparation of a medicament for preventing, treating or reducing the PGD at the CRTH2 receptor in a patient ₂ The mediated disease.

In some such embodiments, the PGD at the CRTH2 receptor is present in the invention ₂ The mediated disease is asthma, chronic obstructive pulmonary disease, allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, eosinophilic bronchitis, food allergy, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, crohn's disease, mastocytosis, autoimmune disease, acne, or reperfusion injury.

In some such embodiments, the autoimmune disorder of the invention is psoriasis, multiple sclerosis, allograft rejection, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus or osteoarthritis.

In another aspect, the invention also relates to a preparation method of the salt of the compound shown in the formula (I) or the crystal form thereof.

The solvent used in the method for preparing the salt or the crystalline form thereof according to the present invention is not particularly limited, and any solvent that can dissolve the starting materials to an extent that does not affect the properties thereof is included in the present invention. Further, many equivalents, substitutions, or equivalents in the art to which this invention pertains, as well as different proportions of solvents, solvent combinations, and solvent combinations described herein, are deemed to be encompassed by the present invention. The invention provides a preferable solvent used in each reaction step.

The experiments for the preparation of the salts or crystalline forms of the invention are described in detail in the examples section. Meanwhile, the invention provides pharmacological property test experiments (such as pharmacokinetic experiments), solubility experiments, stability experiments, hygroscopicity experiments and the like of the salt or the crystal form thereof. Experiments prove that the sodium salt crystal form I and/or the magnesium salt crystal form I have unexpected technical advantages:

1. the sodium salt crystal form I and/or the magnesium salt crystal form I have good stability and good water solubility, and can solve the problems that free acid of the compound shown in the formula (I) is easy to discolor and the purity is reduced.

2. Compared with the compound shown in the formula (I) and other salts of the compound, such as sodium salt crystal form II and calcium salt crystal form I, the sodium salt crystal form I and/or the magnesium salt crystal form I have longer half-life period in beagle dogs and thus have better pharmacokinetic properties.

Therefore, the sodium salt crystal form I and/or the magnesium salt crystal form I have better biological activity and higher stability, and are more suitable for pharmaceutical use.

Definitions and general terms

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entirety. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are described herein.

"crystalline form" or "crystalline form" refers to a solid having a highly regular chemical structure, including, but not limited to, single or multicomponent crystals, and/or polymorphs, solvates, hydrates, clathrates, co-crystals, salts, solvates of salts, hydrates of salts of compounds. Crystalline forms of the substance can be obtained by a number of methods known in the art. Such methods include, but are not limited to, melt crystallization, melt cooling, solvent crystallization, crystallization in a defined space, e.g., in a nanopore or capillary, on a surface or template, e.g., on a polymer, in the presence of an additive such as a co-crystallizing counter molecule, desolventization, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, reactive crystallization, anti-solvent addition, milling, and solvent drop milling, among others.

"amorphous" or "amorphous form" refers to a substance formed when particles (molecules, atoms, ions) of the substance are aperiodically arranged in three-dimensional space, and is characterized by a diffuse, non-peaked, X-ray powder diffraction pattern. Amorphous is a particular physical form of solid material, with locally ordered structural features suggesting a myriad of connections to crystalline materials. Amorphous forms of a substance can be obtained by a number of methods known in the art. Such methods include, but are not limited to, quenching, anti-solvent flocculation, ball milling, spray drying, freeze drying, wet granulation, and solid dispersion techniques, among others.

"solvent" refers to a substance (typically a liquid) that is capable of completely or partially dissolving another substance (typically a solid). Solvents useful in the practice of the present invention include, but are not limited to, water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, methylene chloride, dimethyl sulfoxide, 1, 4-dioxane, ethanol, ethyl acetate, butanol, t-butanol, N-dimethylacetamide, N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropanol, methanol, methyl ethyl ketone, mesitylene, nitromethane, polyethylene glycol, propanol, pyridine, tetrahydrofuran, toluene, xylene, mixtures thereof, and the like.

By "anti-solvent" is meant a fluid that facilitates precipitation of the product (or product precursor) from the solvent. The anti-solvent may comprise a cold gas, or a fluid that promotes precipitation by a chemical reaction, or a fluid that reduces the solubility of the product in the solvent; it may be the same liquid as the solvent but at a different temperature, or it may be a different liquid than the solvent.

"solvate" refers to a compound having a solvent on a surface, in a crystal lattice, or on and in a crystal lattice, which may be water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, methylene chloride, dimethyl sulfoxide, 1, 4-dioxane, ethanol, ethyl acetate, butanol, t-butanol, N-dimethylacetamide, N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropanol, methanol, methyl ethyl ketone, methyl pyrrolidone, mesitylene, nitromethane, polyethylene glycol, propanol, pyridine, tetrahydrofuran, toluene, xylene, mixtures thereof, and the like. A specific example of a solvate is a hydrate, wherein the solvent on the surface, in the crystal lattice or on the surface and in the crystal lattice is water. The hydrates may or may not have other solvents than water on the surface of the substance, in the crystal lattice or both.

Crystalline forms can be identified by a variety of techniques, such as X-ray powder diffraction (XRPD), infrared absorption spectroscopy (IR), melting point methods, Differential Scanning Calorimetry (DSC), thermogravimetric analysis (TGA), nuclear magnetic resonance methods, raman spectroscopy, X-ray single crystal diffraction, dissolution calorimetry, Scanning Electron Microscopy (SEM), quantitative analysis, solubility, and dissolution rate, and the like.

Information such as change, crystallinity, crystal structure state and the like of the crystal form can be detected by X-ray powder diffraction (XRPD), and the method is a common means for identifying the crystal form. The peak positions of the XRPD patterns depend primarily on the structure of the crystalline form, being relatively insensitive to experimental details, while their relative peak heights depend on a number of factors related to sample preparation and instrument geometry. Accordingly, in some embodiments, the crystalline form of the present invention is characterized by an XRPD pattern having certain peak positions, substantially as shown in the XRPD patterns provided in the figures of the present invention. Also, the 2 θ measurement of the XRPD pattern may have experimental error, and the 2 θ measurement of the XRPD pattern may be slightly different from instrument to instrument and from sample to sample, so the 2 θ value cannot be considered absolute. The diffraction peaks have a tolerance of ± 0.2 ° according to the conditions of the instrument used in the test.

Differential Scanning Calorimetry (DSC) is to measure the temperature of a sample and an inert reference substance (usually alpha-Al) by continuously heating or cooling under the control of a program ₂ O ₃ ) The energy difference therebetween varies with temperature. The endothermic peak height of the DSC curve depends on many factors related to sample preparation and instrument geometry, while the peak position is relatively insensitive to experimental details. Thus, in some embodiments, the crystalline form of the present invention is characterized by a DSC profile with characteristic peak positions substantially as shown in the DSC profiles provided in the figures of the present invention. Meanwhile, the DSC profile may have experimental errors, and the peak position and peak value of the DSC profile may slightly differ between different instruments and different samples, so the peak position or peak value of the DSC endothermic peak cannot be regarded as absolute. The endothermic peak has a tolerance of + -3 deg.C depending on the instrument used in the experiment.

Thermogravimetric analysis (TGA) is a technique for measuring the change in mass of a substance with temperature under program control, and is suitable for examining the loss of a solvent in a crystal or the sublimation and decomposition of a sample, and it can be presumed that the crystal contains crystal water or a crystal solvent. The change in mass shown by the TGA profile depends on many factors such as sample preparation and instrumentation; the mass change of the TGA detection varies slightly from instrument to instrument and from sample to sample. There is a tolerance of + -0.1% for mass change depending on the condition of the instrument used in the test.

In the context of the present invention, the 2 θ values in the X-ray powder diffraction pattern are all in degrees (°).

The term "substantially as shown" means that at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of the peaks in the X-ray powder diffraction pattern or DSC pattern or raman spectrum or infrared spectrum are shown in the figure.

When referring to a spectrogram or/and data appearing in a graph, "peak" refers to a feature that one skilled in the art would recognize as not being attributable to background noise.

The present invention relates to salts of said 2- (5-fluoro-3- (1- ((4-fluorophenyl) sulfonyl) piperidin-4-yl) -2-methyl-1H-indol-1-yl) acetic acid and/or crystalline forms thereof, which exist in substantially pure crystalline form.

By "substantially pure" is meant that a crystalline form is substantially free of one or more additional crystalline forms, i.e., the crystalline form is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.6%, or at least 99.7%, or at least 99.8%, or at least 99.9% pure, or the crystalline form contains additional crystalline forms, the percentage of which in the total volume or weight of the crystalline form is less than 20%, or less than 10%, or less than 5%, or less than 3%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.

By "substantially free" is meant that the percentage of one or more other crystalline forms in the total volume or weight of the crystalline form is less than 20%, or less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1%, or less than 0.5%, or less than 0.1%, or less than 0.01%.

"relative intensity" (or "relative peak height") in an XRPD pattern refers to the ratio of the intensity of the first strong peak to the intensity of the other peaks when the intensity of the first strong peak is 100% of all the diffraction peaks in the X-ray powder diffraction pattern.

In the context of the present invention, the word "about" or "approximately" when used or whether used, means within 10%, suitably within 5%, and especially within 1% of a given value or range. Alternatively, the term "about" or "approximately" means within an acceptable standard error of the mean, for one of ordinary skill in the art. Whenever a number is disclosed with a value of N, any number within the values of N +/-1%, N +/-2%, N +/-3%, N +/-5%, N +/-7%, N +/-8% or N +/-10% is explicitly disclosed, wherein "+/-" means plus or minus.

"room temperature" in the present invention means a temperature of from about 10 ℃ to about 40 ℃. In some embodiments, "room temperature" refers to a temperature of from about 20 ℃ to about 30 ℃; in other embodiments, "room temperature" refers to 20 ℃,22.5 ℃,25 ℃,27.5 ℃, and the like.

Pharmaceutical compositions, formulations, administration and uses of the salts or crystalline forms thereof of the invention

The pharmaceutical composition of the invention is characterized by comprising salts and/or crystal forms of the compounds shown in the formula (I) and pharmaceutically acceptable carriers, auxiliary agents or excipients. The amount of the salt of the compound or crystalline form thereof in the pharmaceutical composition of the present invention is effective to detectably treat or alleviate asthma or allergic rhinitis in a patient. The pharmaceutical compositions of the present invention may also optionally comprise other therapeutic and/or prophylactic ingredients.

Suitable carriers, adjuvants and excipients are well known to those skilled in the art and are described in detail, for example, in Ansel h.c.et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, philidelphia; gennaro a.r.et al, Remington: the Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago.

The skilled person is knowledgeable and skilled in the art to enable them to select suitable amounts of suitable pharmaceutically acceptable excipients for use in the present invention. Furthermore, there is a large amount of resources available to the skilled person, who describes pharmaceutically acceptable excipients and is used to select suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (The American Pharmaceutical Association and The Pharmaceutical Press).

Various carriers for formulating pharmaceutically acceptable compositions, and well known techniques for their preparation, are disclosed in Remington, The Science and Practice of Pharmacy,21st edition,2005, ed.D.B.Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds.J.Swarbrick and J.C.Boylan, 1988. Annu 1999, Marcel Dekker, New York, The contents of each of which are incorporated herein by reference. The use of any carrier is within the scope of the invention except for any commonly used carrier which is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or interacting in a deleterious manner with any other ingredient in a pharmaceutically acceptable composition.

The pharmaceutical compositions of the present invention are prepared using techniques and methods known to those skilled in the art. Some commonly used methods in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).

In another aspect, the invention relates to a process for preparing a pharmaceutical composition comprising a salt of a compound of the invention or a crystalline form thereof and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or combination thereof, which process comprises admixing the ingredients. Pharmaceutical compositions comprising a salt of a compound of the invention, or a crystalline form thereof, may be prepared by mixing at, for example, ambient temperature and atmospheric pressure.

The salts of the compounds of the present invention or crystalline forms thereof are generally formulated in a dosage form suitable for administration to a patient by a desired route. For example, dosage forms include those suitable for the following routes of administration: (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and reconstituted powders; (3) transdermal administration, such as transdermal patches; (4) rectal administration, e.g., suppositories; (5) inhalation, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes, sprays, foams and gels.

The pharmaceutical composition provided by the present invention may be provided in soft or hard capsules, which may be prepared from gelatin, methylcellulose, starch or calcium alginate. The hard gelatin capsules, also known as Dry Fill Capsules (DFC), consist of two segments, one inserted into the other, thus completely encapsulating the active ingredient. Soft Elastic Capsules (SEC) are soft, spherical shells, such as gelatin shells, which are plasticized by the addition of glycerol, sorbitol or similar polyols. The soft gelatin shell may contain a preservative to prevent microbial growth. Suitable preservatives are those as described herein, including methyl and propyl parabens, and sorbic acid. The liquid, semi-solid and solid dosage forms provided by the present invention may be encapsulated in a capsule. Suitable liquid and semi-solid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions may be as described in U.S. patent nos.4,328,245; 4,409,239 and 4,410,545. The capsules may also be coated as known to those skilled in the art to improve or maintain dissolution of the active ingredient.

In one embodiment, the treatment methods of the present invention comprise administering to a patient in need thereof a safe and effective amount of a salt of a compound of the present invention or a crystalline form thereof or a pharmaceutical composition comprising a salt of a compound of the present invention or a crystalline form thereof. Various embodiments of the present invention encompass the treatment of the diseases mentioned herein by administering to a patient in need thereof a safe and effective amount of a salt of a compound of the present invention or a crystalline form thereof or a pharmaceutical composition comprising a salt of a compound of the present invention or a crystalline form thereof.

In one embodiment, the salt of the compound of the present invention or a crystalline form thereof or a pharmaceutical composition comprising the salt of the compound of the present invention or a crystalline form thereof may be administered by any suitable route of administration, including systemic administration and topical administration. Systemic administration includes oral, parenteral, transdermal and rectal administration. Typical parenteral administration refers to administration by injection or infusion, including intravenous, intramuscular, and subcutaneous injection or infusion. Topical administration includes application to the skin and intraocular, otic, intravaginal, inhalation, and intranasal administration. In one embodiment, a salt of a compound of the invention or a crystalline form thereof or a pharmaceutical composition comprising a salt of a compound of the invention or a crystalline form thereof may be administered orally. In another embodiment, a salt of a compound of the invention or a crystalline form thereof or a pharmaceutical composition comprising a salt of a compound of the invention or a crystalline form thereof may be administered by inhalation. In yet another embodiment, the salt of the compound of the present invention or a crystalline form thereof or a pharmaceutical composition comprising the salt of the compound of the present invention or a crystalline form thereof may be administered intranasally.

In one embodiment, the salt of the compound of the present invention or a crystalline form thereof or a pharmaceutical composition comprising the salt of the compound of the present invention or a crystalline form thereof may be administered once or several times at different time intervals within a specified time period according to a dosing regimen. For example, once, twice, three times or four times daily. In one embodiment, the administration is once daily. In yet another embodiment, the administration is twice daily. The administration may be carried out until the desired therapeutic effect is achieved or the desired therapeutic effect is maintained indefinitely. Suitable dosing regimens for a salt of a compound of the invention or a crystalline form thereof, or a pharmaceutical composition comprising a salt of a compound of the invention or a crystalline form thereof, depend on the pharmacokinetic properties of the salt of the compound, such as absorption, distribution and half-life, which can be determined by the skilled person. In addition, suitable dosing regimens of the salts of the compounds of the invention or crystalline forms thereof, or pharmaceutical compositions comprising the salts of the compounds of the invention or crystalline forms thereof, including the duration of the regimen, will depend upon the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and experience of the skilled artisan. Such skilled persons will also appreciate that appropriate dosage regimens may require adjustment to the individual patient's response to the dosage regimen, or to the individual patient's need for change over time.

The salts of the compounds of the present invention or crystalline forms thereof may be administered concurrently with, before or after one or more other therapeutic agents. The salts of the compounds of the present invention or their crystalline forms may be administered separately from the other therapeutic agents by the same or different routes of administration, or in the form of the same pharmaceutical compositions.

The salts of the compounds of the invention or their crystalline forms may be used in combination with the treatment of PGD at the CRTH2 receptor ₂ Drugs of mediated diseases and conditions, and the like, that form combinations of drugs of the invention, such as: salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilomilast, TNF-alpha converting enzyme (TACE) inhibitors, blocking monoclonal antibodies to IL-4 or IL-5, soluble receptors for IL-4 or IL-5, and zileuton, and salts and compositions thereof, and the like, or a salt of the compound of the invention or a crystalline form thereof may be administered in combination with a physical means such as light therapy or electrical stimulation.

For an individual of about 50-70kg, the pharmaceutical compositions and combinations of the present invention may be in unit dosage form containing about 1-1000mg or a suitable dosage of the active ingredient. The therapeutically effective amount of the compound, salt of the compound, pharmaceutical composition or combination thereof will depend on the species, weight, age and condition of the subject, the disease or disorder being treated, or the severity thereof. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each active ingredient required to prevent, treat or inhibit the progression of the disease or disorder.

The above cited dose profiles have been demonstrated in vitro and in vivo tests using beneficial mammals (e.g., mice, rats, dogs, monkeys) or isolated organs, tissues and specimens thereof.

In one embodiment, the amount of the compound in a therapeutically effective dose of a salt of a compound of the invention is from about 0.1mg to about 2,000mg per day. The pharmaceutical composition thereof should provide a dose of the compound of about 0.1mg to about 2,000 mg. In a particular embodiment, the pharmaceutical dosage unit form is prepared to provide from about 1mg to about 2,000mg, from about 10mg to about 1,000mg of the principal active ingredient or a combination of principal ingredients per dosage unit form.

The salt of the compound provided by the invention or the crystal form and the pharmaceutical composition thereof can be used for preparing medicines for preventing and treatingThe medicine for treating or relieving asthma and allergic rhinitis of mammals including human beings can also be used for preparing medicines for preventing, treating or relieving PGD at CRTH2 receptor of mammals including human beings ₂ A pharmaceutical product for the treatment of a disease mediated thereby.

In particular, the amount of compound in the pharmaceutical compositions of the present invention is effective to detectably antagonize PGD at the CRTH2 receptor ₂ The salts of the compounds of the invention or their crystalline forms are useful as therapeutics for treating PGD at the CRTH2 receptor ₂ Drugs for mediated diseases such as asthma and allergic rhinitis.

The salts of the compounds of the present invention or their crystalline forms may be used in, but are in no way limited to, the prevention, treatment or alleviation of PGD at the CRTH2 receptor by administering to a patient an effective amount of a salt of the compound of the present invention or a crystalline form or a pharmaceutical composition thereof ₂ The mediated disease. The PGD at the CRTH2 receptor ₂ The mediated disease is asthma, chronic obstructive pulmonary disease, allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, eosinophilic bronchitis, food allergy, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, crohn's disease, mastocytosis, autoimmune disease, acne, or reperfusion injury; wherein the autoimmune disorder is psoriasis, multiple sclerosis, allograft rejection, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus or osteoarthritis.

An "effective amount" or "effective dose" of a salt of a compound of the invention or a crystalline form or pharmaceutically acceptable composition thereof refers to an amount effective to treat or reduce the severity of one or more of the conditions mentioned herein. The salt of the compound of the present invention or a crystalline form or pharmaceutically acceptable composition thereof may be administered in any amount and by any route effective to treat or reduce the severity of the disease in accordance with the methods of the present invention. The exact amount necessary will vary depending on the patient, depending on the race, age, general condition of the patient, severity of infection, particular factors, mode of administration, and the like. The salts of the compounds of the present invention or crystalline forms or pharmaceutically acceptable compositions thereof may be administered in combination with one or more other therapeutic agents, as discussed herein.

The salts of the compounds of the present invention or their crystalline forms and pharmaceutical compositions are useful in veterinary therapy for pets, animals of the introduced breed and mammals in farm animals, in addition to human therapy. Examples of other animals include horses, dogs, and cats.

Drawings

Figure 1 is an X-ray powder diffraction (XRPD) pattern of the sodium salt form I of the compound of formula (I).

FIG. 2 is a Differential Scanning Calorimetry (DSC) chart of the sodium salt form I of the compound of formula (I).

FIG. 3 is a thermogravimetric analysis (TGA) plot of the sodium salt form I of the compound of formula (I).

Figure 4 is an X-ray powder diffraction (XRPD) pattern of crystalline form II of the sodium salt of the compound of formula (I).

FIG. 5 is a Differential Scanning Calorimetry (DSC) profile of the sodium salt form II of the compound of formula (I).

FIG. 6 is a thermogravimetric analysis (TGA) profile of the sodium salt form II of the compound of formula (I).

FIG. 7 is an X-ray powder diffraction (XRPD) pattern of magnesium salt form I of the compound of formula (I).

FIG. 8 is a Differential Scanning Calorimetry (DSC) chart of the magnesium salt form I of the compound of formula (I).

FIG. 9 is a thermogravimetric analysis (TGA) profile of magnesium salt form I of the compound of formula (I).

Figure 10 is an X-ray powder diffraction (XRPD) pattern of calcium salt form I of the compound of formula (I).

FIG. 11 is a Differential Scanning Calorimetry (DSC) profile of the calcium salt form I of the compound of formula (I).

FIG. 12 is a thermogravimetric analysis (TGA) profile of calcium salt form I of the compound of formula (I).

Detailed Description

The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.

The X-ray powder diffraction analysis method used by the invention comprises the following steps: an Empyrean diffractometer, using Cu-Ka radiation (45KV,40mA) to obtain an X-ray powder diffraction pattern. The powdered sample was prepared as a thin layer on a single crystal silicon sample holder, placed on a rotating sample stage and analyzed in 0.0167 ° steps over a range of 3 ° -60 °. Data Collector software was used to collect Data, HighScore Plus software processed the Data, and Data Viewer software read the Data.

The Differential Scanning Calorimetry (DSC) analysis method used in the invention comprises the following steps: differential scanning calorimetry was performed using a TA Q2000 module with a thermoanalytical controller. Data were collected and analyzed using TA Instruments Thermal Solutions software. About 1-5mg of the sample was accurately weighed into a specially made aluminum crucible with a lid and the sample analysis was performed from room temperature to about 300 ℃ using a linear heating device at 10 ℃/min. During use, the DSC cell was purged with dry nitrogen.

The Thermal Gravimetric Analysis (TGA) method used in the invention is as follows: thermogravimetric analysis was performed using a TA Q500 module with a thermoanalytical controller. Data were collected and analyzed using TA Instruments Thermal Solutions software. About 10-30mg of the sample was placed in a platinum crucible and the sample analysis was performed from room temperature to about 300 c using a linear heating device at 10 c/min. During use, the TGA cell was purged with dry nitrogen.

The solubility of the invention is measured by an Agilent 1200 high performance liquid chromatograph DAD/VWD detector, and the type of a chromatographic column is Agilent XDB-C18(4.6 multiplied by 50mm,5 mu m). The detection wavelength is 266nm, the flow rate is 1.0mL/min, the column temperature is 35 ℃, and the flow rate of a mobile phase A: acetonitrile/0.01M ammonium acetate-10/90 (V/V), analytical methods: acetonitrile/mobile phase a ═ 70/30(V/V), run time: for 10 minutes.

The moisture absorption of the invention is measured by adopting a DVS INT-Std type dynamic moisture and gas adsorption analyzer of Surface Measurement Systems company in England, and the humidity test range is as follows: 0% -95%, airflow: 200mL/min, temperature: 25 ℃, test point: one test point was taken per liter of 5% humidity.

Detailed description of the preferred embodiment

Comparative example

The inventor finds through experiments that, in several crystal forms disclosed in prior art WO2016037591a1, compared with other crystal forms, the crystal form I of the compound shown in formula (I) (2- (5-fluoro-3- (1- ((4-fluorophenyl) sulfonyl) piperidin-4-yl) -2-methyl-1H-indol-1-yl) acetic acid) is more stable and has better pharmacokinetic properties, so that, in the present invention, the inventor selects the crystal form I of the compound shown in formula (I) with better properties as a reference substance to research the salt of the compound shown in formula (I) and the crystal form thereof. In particular, reference is made to example 24 in international application WO2016037591a1 for the synthesis of the compound of formula (I) in crystalline form I.

Examples

EXAMPLE 1 sodium salt form I

1. Preparation of sodium salt form I

Adding the compound shown as the formula (I) in the crystal form I (405.4mg,0.86mmol) into ethanol (4.0mL) at room temperature, pulping for 1h, adding a solution of sodium isooctanoate (173mg,1.01mmol) in ethanol (2.0mL), and stirring for reacting for 5 h. Suction filtration and drying of the filter cake under vacuum at 60 ℃ overnight gave a white solid (278.6mg, 68.83%).

2. Identification of sodium salt form I

(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, having the following characteristic peaks expressed in degrees 2 θ: 5.97 °,8.73 °,9.15 °,9.70 °,10.10 °,10.40 °,10.88 °,11.87 °,12.82 °,14.89 °,15.35 °,15.74 °,16.28 °,16.78 °,17.05 °,17.30 °,17.83 °,18.36 °,18.91 °,19.51 °,20.16 °,20.61 °,21.26 °,21.68 °,21.98 °,22.30 °,22.60 °,23.37 °,23.80 °,24.08 °,25.02 °,25.35 °,25.74 °,26.76 °,27.59 °,28.25 °,28.57 °,29.03 °,29.67 °,30.51 °,31.29 °,31.69 °,32.84 °,33.49 °,35.06 °,35.52 °,36.67 °,37.84 °,38.59 °,38.98 °, and 40.37 °, with a tolerance of ± 0.2 °. The XRPD pattern of crystalline form I of the sodium salt prepared according to the method of example 1 of the present invention is substantially as shown in figure 1.

(2) Identification by TA Q2000 Differential Scanning Calorimetry (DSC) analysis: the scan rate was 10 ℃/min, contained an endotherm of 210.79 ℃, with a margin of error of ± 3 ℃. The DSC diagram of crystalline form I of the sodium salt prepared according to the method of example 1 of the present invention is substantially as shown in figure 2.

(3) Thermogravimetric analysis (TGA) identification by TA Q500: the heating rate is 10 ℃/min, and when the temperature is heated to 154.59 ℃, the weight loss is 0.5670 percent. The TGA profile of crystalline form I of the sodium salt prepared according to the method of example 1 of the present invention is substantially as shown in figure 3.

Example 2 sodium salt form II

1. Preparation of sodium salt form II

The method comprises the following steps: adding the compound shown as the formula (I) in the crystal form I (202.5mg and 0.43mmol) into ethyl acetate (2.0mL) at room temperature, pulping for 40min, adding a 1.0mol/L sodium hydroxide solution (1.0mL and 1.0mmol), adding n-heptane (2.0mL), and stirring for reacting for 2 h. After allowing to stand at room temperature for 10h, it was evaporated, filtered with suction, and the filter cake was washed with ethyl acetate (1.0mL) and n-heptane (1.0 mL. times.2) and dried under vacuum at 60 ℃ overnight to give a white solid (35.5mg, 17.6%).

The second method comprises the following steps: adding a compound shown as a compound formula (I) in a crystal form I (1006.4mg,2.14mmol) into tetrahydrofuran (5.0mL), stirring at 60 ℃ for dissolving, adding a water (0.5mL) solution of sodium carbonate (125mg,1.18mmol), keeping the temperature and stirring for 2.5h, and naturally cooling to room temperature. After allowing to stand at room temperature and volatilize for 12h, ethyl acetate (3.0mL) is added to dissolve, and then n-heptane (3.0mL) is added to stir for crystallization for 2 h. Suction filtered and dried under vacuum at 80 ℃ for 24h to give a white solid (915.3mg, 91.09%).

2. Identification of sodium salt form II

(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, having the following characteristic peaks expressed in degrees 2 θ: 5.06 °,8.28 °,8.81 °,9.09 °,10.07 °,11.42 °,12.45 °,13.31 °,13.63 °,14.43 °,15.12 °,16.12 °,16.45 °,18.17 °,18.49 °,18.74 °,19.09 °,20.16 °,20.79 °,22.01 °,22.75 °,23.09 °,23.97 °,25.25 °,26.06 °,26.93 °,27.53 °,28.04 °,28.67 °,29.57 °,30.09 °,30.46 °,31.99 °,33.21 °,34.55 °,36.63 °,38.18 °,38.95 °,40.92 °,42.64 °,43.42 ° and 44.95 °, with an error tolerance of ± 0.2 °. The XRPD pattern of crystalline form II of the sodium salt prepared according to the method of example 2 of the present invention is substantially as shown in figure 4.

(2) Identification by TA Q2000 Differential Scanning Calorimetry (DSC) analysis: the scan rate was 10 ℃/min, contained endothermic peaks at 104.40 ℃ and 184.48 ℃, with a margin of error of ± 3 ℃. The DSC diagram of the sodium salt form II prepared according to the method of example 2 of the present invention is substantially as shown in figure 5.

(3) Thermogravimetric analysis (TGA) identification by TA Q500: the heating rate is 10 ℃/min, the weight loss is 5.606 percent when the temperature is heated to 79.98 ℃, the weight loss is 1.388 percent again when the temperature is continuously heated to 139.30 ℃, and the weight loss is 0.7184 percent for the third time when the temperature is heated to 182.72 ℃. The TGA profile of crystalline form II of the sodium salt prepared according to the method of example 2 of the present invention is substantially as shown in figure 6.

Example 3 magnesium salt form I

1. Preparation of magnesium salt form I

Adding the crystal form I (505mg,1.072mmol) of the compound shown in the formula (I) into ethanol (5.0mL), heating to 60 ℃, pulping for 1.5h, then adding a water (1.0mL) solution of sodium carbonate (60mg,0.565mmol), stirring for reacting for 0.5h, then adding a water (1.0mL) solution of magnesium chloride (53mg,0.53mmol), stirring for reacting for 4h, and naturally cooling to room temperature. Suction filtration was performed, and the filter cake was washed with water (2.0 mL. times.2) and dried overnight under vacuum at 60 ℃ to give a white solid (393mg, 39.89%).

2. Identification of magnesium salt form I

(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, having the following characteristic peaks expressed in degrees 2 θ: 5.15 °,8.40 °,9.25 °,10.31 °,12.19 °,13.26 °,14.28 °,14.62 °,15.50 °,16.33 °,16.78 °,17.38 °,18.55 °,19.12 °,20.24 °,20.61 °,21.10 °,21.64 °,21.88 °,22.06 °,22.99 °,23.59 °,23.95 °,24.55 °,25.81 °,26.28 °,26.69 °,27.11 °,27.57 °,28.51 °,28.93 °,29.47 °,30.18 °,30.77 °,31.50 °,32.09 °,32.99 °,34.05 °,35.18 °,37.05 °,38.80 °,39.81 °,40.41 °,42.10 °,44.08 °, and 49.00 °, with an error tolerance of ± 0.2 °. The XRPD pattern of form I of the magnesium salt prepared according to the method of example 3 of the present invention is substantially as shown in figure 7.

(2) Identification by TA Q2000 Differential Scanning Calorimetry (DSC) analysis: the scan rate was 10 ℃/min, contained an endotherm of 160.86 ℃, with a margin of error of ± 3 ℃. The DSC diagram of form I of the magnesium salt prepared according to the method of example 3 of the present invention is substantially as shown in figure 8.

(3) Thermogravimetric analysis (TGA) identification by TA Q500: the heating rate is 10 ℃/min, the weight loss is 4.377 percent when the temperature is heated to 94.45 ℃, and the weight loss is 5.385 percent again when the temperature is continuously heated to 130.13 ℃. The TGA profile of magnesium salt form I prepared according to the method of example 3 of the present invention is substantially as shown in figure 9.

Example 4 calcium salt form I

1. Preparation of calcium salt form I

Adding the compound crystal form I shown in the formula (I) (503mg,1.067mmol) into ethanol (1.0mL) at room temperature, pulping for 40min, adding a water (0.5mL) solution in which calcium hydroxide (44.8mg,0.574mmol) is suspended, precipitating a large amount of solid, adding ethanol (10.0mL), and stirring overnight. Suction filtered and dried overnight under vacuum at 60 ℃ to give a white solid (500mg, 50.1%).

2. Identification of calcium salt form I

(1) Identified by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-ka radiation, having the following characteristic peaks expressed in degrees 2 θ: 5.46 °,9.69 °,10.86 °,12.40 °,14.65 °,15.05 °,15.68 °,16.37 °,16.90 °,17.61 °,18.00 °,18.48 °,18.88 °,19.47 °,19.91 °,20.41 °,21.35 °,21.81 °,22.59 °,23.48 °,24.10 °,24.90 °,25.92 °,27.07 °,27.87 °,29.09 °,29.47 °,31.18 °,32.59 °,33.08 °,33.74 °,34.84 °,35.66 °,36.39 °,37.24 °, and 38.28 °, with a tolerance of ± 0.2 °. The XRPD pattern of form I of the calcium salt prepared according to the method of example 4 of the present invention is substantially as shown in figure 10.

(2) Identification by TA Q2000 Differential Scanning Calorimetry (DSC) analysis: the scan rate was 10 ℃/min, contained endothermic peaks at 111.94 ℃ and 204.22 ℃, with a margin of error of ± 3 ℃. The DSC diagram of form I of the calcium salt prepared according to the method of example 4 of the present invention is substantially as shown in figure 11.

(3) Thermogravimetric analysis (TGA) identification by TA Q500: the heating rate is 10 ℃/min, the weight loss is 3.001 percent when the temperature is heated to 88.54 ℃, and the weight loss is 3.815 percent again when the temperature is continuously heated to 168.04 ℃. The TGA profile of crystalline form I of the calcium salt prepared according to the method of example 4 of the present invention is substantially as shown in figure 12.

Example 5 pharmacokinetic experiments on the salts of the invention or crystalline forms thereof

A test sample, i.e. a salt according to the invention or a crystalline form thereof, or as a control example a compound of formula (I) according to the invention in crystalline form I, is filled into capsules for oral administration.

8-12kg of male Beagle dogs were divided into 6 groups of 3 dogs, and capsules containing test samples were orally administered at a dose of 5mg/kg by collecting blood at time points of 0.25,0.5,1.0,2.0,4.0,6.0,8.0,12.0 and 24 hours. A standard curve of the appropriate range is established based on the sample concentration, and the concentration of the test sample in the plasma sample is determined in MRM mode using LC-MS/MS model AB SCIEX API4000 and subjected to quantitative analysis. Pharmacokinetic parameters were calculated according to the drug concentration-time curve using the WinNonLin 6.3 software non-compartmental model method. The results of the experiment are shown in table 1.

TABLE 1 pharmacokinetic experimental data

Test sample	C max (ng/ml)	T 1/2 (h)	T max (h)
				Example 1	4550	7.24	0.83
Example 3	4560	8.72	0.83
				Example 4	995	6.87	1.33
Comparative example	5800	5.15	2.0

And (4) experimental conclusion:

as can be seen from table 1, the sodium salt form I and the magnesium salt form I of the present invention have longer half-lives in beagle dogs than the form I of the compound of formula (I) and the form I of the calcium salt of the compound of formula (I). Therefore, the sodium salt crystal form I and the magnesium salt crystal form I have better pharmacokinetic properties.

Example 6 stability test of the salt of the invention or its crystalline forms

High temperature experiment: taking a proper amount of a batch of test articles, putting the test articles into a flat weighing bottle, spreading the test articles into a thin layer with the thickness of less than or equal to 5mm, standing the test articles for 32 days at 40 ℃ and RH 75%, and sampling stability key items for detection on 5 th, 11 th and 32 th days.

High humidity experiment:taking a proper amount of a test sample, placing the test sample into a flat weighing bottle, spreading the test sample into a thin layer with the thickness of less than or equal to 5mm, placing the test sample for 32 days under the conditions of 25 ℃ and RH 90% +/-5%, and sampling stability key examination items for detection on 5 th, 11 th and 32 th days.

Experiments show that under the conditions of high temperature and high humidity, the salt or the crystal form of the salt has no obvious change in appearance and purity, has good stability effect, and is suitable for pharmaceutical application.

Example 7 hygroscopicity test of the salts of the invention or crystalline forms thereof

A proper amount of sample to be tested is taken, and the hygroscopicity of the sample is tested by adopting a dynamic moisture adsorption instrument. Experiments show that the salt or the crystal form thereof is not easy to be affected by high humidity to deliquesce.

Example 8 solubility testing of salts of the invention or crystalline forms thereof

Placing a sample to be tested in water with the temperature of 37 ℃ to prepare supersaturated turbid liquid, shaking for 24 hours, filtering, taking filtrate, and detecting the solubility of the target sample in the water by using an HPLC method. Experiments show that the salt or the crystal form thereof has higher solubility in water, so the salt or the crystal form thereof has better drug forming property and is suitable for preparation development.

The above description is only a basic description of the present invention, and any equivalent changes made according to the technical solution of the present invention should fall within the protection scope of the present invention.

In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Moreover, various embodiments or examples and features of various embodiments or examples described in this specification can be combined and combined by one skilled in the art without being mutually inconsistent.

Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.

Claims (10)

1. A salt of a compound of formula (I),

wherein the salt is a sodium salt or a magnesium salt;

the sodium salt is a sodium salt crystal form I, and an X-ray powder diffraction pattern of the sodium salt crystal form I has diffraction peaks at the following 2 theta angles: 5.97 ° ± 0.2 °,16.28 ° ± 0.2 °,17.83 ° ± 0.2 °,18.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.61 ° ± 0.2 °,22.60 ° ± 0.2 °;

the magnesium salt is a magnesium salt crystal form I, and an X-ray powder diffraction pattern of the magnesium salt crystal form I has diffraction peaks at the following 2 theta angles: 16.33 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,28.93 ° ± 0.2 °.

2. The salt of claim 1, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.97 ° ± 0.2 °,11.87 ° ± 0.2 °,12.82 ° ± 0.2 °,16.28 ° ± 0.2 °,17.83 ° ± 0.2 °,18.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.61 ° ± 0.2 °,21.26 ° ± 0.2 °,22.60 ° ± 0.2 °;

the magnesium salt is a magnesium salt crystal form I, and an X-ray powder diffraction pattern of the magnesium salt crystal form I has diffraction peaks at the following 2 theta angles: 13.26 ° ± 0.2 °,16.33 ° ± 0.2 °,16.78 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,22.06 ° ± 0.2 °,28.93 ° ± 0.2 °.

3. The salt according to claim 1 or 2, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern with diffraction peaks at the following 2 Θ angles: 5.97 ° ± 0.2 °,8.73 ° ± 0.2 °,9.15 ° ± 0.2 °,9.70 ° ± 0.2 °,10.10 ° ± 0.2 °,10.40 ° ± 0.2 °,10.88 ° ± 0.2 °,11.87 ° ± 0.2 °,12.82 ° ± 0.2 °,14.89 ° ± 0.2 °,15.35 ° ± 0.2 °,15.74 ° ± 0.2 °,16.28 ° ± 0.2 °,16.78 ° ± 0.2 °,17.05 ° ± 0.2 °,17.30 ° ± 0.2 °,17.83 ° ± 0.2 °,18.36 ° ± 0.91 ° ± 0.2 °,19.51 ° ± 0.2 °,20.16 ° ± 0.61 °, 20.21.26 ° ± 0.2.2 ± 0.26 ° ± 0.2 °,18 ° ± 0.2 °,19 ° ± 0.2.2 ° ± 0.2 °,20.2 °,20.61 ° ± 0.26 ° ± 0.2 °, 2.2 °,2 ° ± 0.2.2 °,2 °, 2.2 °,2 ° ± 0.2 °, 2.2.2.2 ° ± 0.2 °,2 ° ± 0.2.2.2 °, 2.2 °,2 °, 2.2.2 ° ± 0.2 °,2 °, 2.2.2 °,2 °, 2.2 °,2 ° 0.2.2 ° 0.2 °,2 ° 0.2 °, 2.2 ° 0.2 °, 0.2 ° 0.2.2.2 °, 0.2 ° 0.2.2 °, 0.2 °,2 °, 0.2 °, 2.2 ° 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °, 0.2 °,0, 33.49 ° ± 0.2 °,35.06 ° ± 0.2 °,35.52 ° ± 0.2 °,36.67 ° ± 0.2 °,37.84 ° ± 0.2 °,38.59 ° ± 0.2 °,38.98 ° ± 0.2 °,40.37 ° ± 0.2 °;

the magnesium salt is a magnesium salt crystal form I, and an X-ray powder diffraction pattern of the magnesium salt crystal form I has diffraction peaks at the following 2 theta angles: 5.15 ° ± 0.2 °,8.40 ° ± 0.2 °,9.25 ° ± 0.2 °,10.31 ° ± 0.2 °,12.19 ° ± 0.2 °,13.26 ° ± 0.2 °,14.28 ° ± 0.2 °,14.62 ° ± 0.2 °,15.50 ° ± 0.2 °,16.33 ° ± 0.2 °,16.78 ° ± 0.2 °,17.38 ° ± 0.2 °,18.55 ° ± 0.2 °,19.12 ° ± 0.2 °,20.24 ° ± 0.2 °,20.61 ° ± 0.2 °,21.10 ° ± 0.2 °,21.64 ° ± 0.2 °,21.88 ° ± 0.2 °,22.06 ° ± 0.2 °,22.99 ° ± 0.2 °,23.59 ° ± 0.2 °,23.95 ° ± 0.2.2 ° ± 0.2 °, 2.2 ° ± 0.2 °, 2.9 ° ± 0.9 ° ± 0.2 °, 2.2 °,2 °, 2.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.2 °, 2.9 ° ± 0.9 ° ± 0.2 °, 2.2.2.2 °, 2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2.2 °, 2.2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °,2 °, 2.2 °,2 °, 2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.2.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.2 °, 2.2.2.2.2.9 ° ± 0.2.2 °, 2.2.2 °,2 °, 2.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2.9 ° ± 0.9 ° ± 0.2.2 °,2 °, 2.9 ° ± 0.9 ° ± 0.2 °,2 °, 2.2 °, 2.2.2 °,2 °, 2.2 °,2 °, 2.2.9 ° ± 0, 42.10 ° ± 0.2 °,44.08 ° ± 0.2 °,49.00 ° ± 0.2 °.

4. The salt of claim 1, wherein the sodium salt is sodium salt form I having an X-ray powder diffraction pattern substantially as shown in figure 1;

the magnesium salt is magnesium salt form I having an X-ray powder diffraction pattern substantially as shown in figure 7.

5. The salt of claim 1, wherein the sodium salt is sodium salt form I having a differential scanning calorimetry trace comprising an endothermic peak at 210.79 ℃ ± 3 ℃;

the magnesium salt is a magnesium salt crystal form I, and a differential scanning calorimetry chart of the magnesium salt crystal form I comprises an endothermic peak at 160.86 +/-3 ℃.

6. The salt of claim 5, wherein the sodium salt is sodium salt form I having a differential scanning calorimetry trace substantially as shown in FIG. 2;

the magnesium salt is magnesium salt form I having a differential scanning calorimetry pattern substantially as shown in figure 8.

7. A pharmaceutical composition comprising a salt of any one of claims 1-6, and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, or combination thereof.

8. Use of a salt according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 in the manufacture of a medicament for preventing, treating or ameliorating PGD at the CRTH2 receptor in a patient ₂ The mediated disease.

9. The use according to claim 8, wherein the PGD at the receptor CRTH2 is present ₂ The mediated disease is asthma, chronic obstructive pulmonary disease, allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, eosinophilic bronchitis, food allergy, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, crohn's disease, mastocytosis, autoimmune disease, acne, or reperfusion injury.

10. The use according to claim 9, wherein the autoimmune disorder is psoriasis, multiple sclerosis, allograft rejection, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus or osteoarthritis.

Images